Quinaprilat: A review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 10, 2009, Pages 1337-1347

  Kieback, Arne Georg ^a   Felix, Stephan B ^a   Reffelmann, Thorsten ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

ACE inhibitor; Intravenous; Pharmacokinetics; Quinapril; Quinaprilat

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; BENAZEPRIL; BENAZEPRILAT; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; CILOSTAZOL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; ENALAPRIL; ENALAPRILAT; FOSINOPRIL; FOSINOPRILAT; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; METOPROLOL; MOEXIPRIL; NITRENDIPINE; NITROPRUSSIDE SODIUM; PD 109488; PD 113413; PERINDOPRIL; PERINDOPRILAT; QUINAPRIL; QUINAPRILAT; RAMIPRIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALBUMINURIA; ANGIONEUROTIC EDEMA; ANTICOAGULATION; ARTERY DISEASE; ARTERY INTIMA PROLIFERATION; AUTOIMMUNE DISEASE; BLOOD PRESSURE REGULATION; CARCINOGENICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COUGHING; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISSOCIATION; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FETUS DEATH; GLOMERULUS FILTRATION; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEART TRANSPLANTATION; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; LACTATION; LIVER CIRRHOSIS; MEDLINE; MUTAGENICITY; NEUTROPENIA; NEWBORN DEATH; NEWBORN MORBIDITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PLASMA RENIN ACTIVITY; PREGNANCY; RASH; RENOVASCULAR HYPERTENSION; RESTENOSIS; REVIEW; RISK; SIDE EFFECT; TASTE DISORDER; TERATOGENICITY; TOXICOLOGY; ULCER; URINE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; FEMALE; HALF-LIFE; HEART FAILURE; HUMANS; HYPERTENSION; PREGNANCY; TETRAHYDROISOQUINOLINES;

ANIMALIA;

EID: 70349404397     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903282773     Document Type: Review

References (86)

1. Kaplan HR, Taylor DG, Olson SC, et al. Quinapril a preclinical review of the pharmacology, pharmacokinetics and toxicology. Angiology 1989;40:335-350 • Valuable preclinical data.
2. Pines A, Fisman EZ. ACE inhibition with moexipril:a review of potential effects beyond blood pressure control. Am J Cardiovasc Drugs 2003;3(5):351-360 (Pubitemid 37369368)
3. Breslin E, Posvar E, Neub M, et al. A pharmacodynamic and pharmakokinetic comparison of intravenous quinaprilat and oral quinapril. J Clin Pharmacol 1996;36:414-421 •• Important data comparing differences between the oral prodrug and the intravenous active metabolite. (Pubitemid 26165734)
4. Olson SC, Horvath AM, Michniewicz BM, et al. The clinical pharmacokinetics of quinapril. Angiology 1989;40:351-359 • Valuable pharmacokinetic overview.
5. Cetnarowski-Cropp AB. Quinapril: a new second-generation ACE inhibitor. DICP 1991;25(5):499-504
6. Knütter I, Wollesky C, Kottra G, et al. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Phamacol Exp Ther 2008;327(2):432-441
7. Kaplan HR, Taylor DG, Olson SC, et al. Quinapril: a preclinical review of the pharmacology, pharmacokientics, and toxicology. Angiology 1989;40:335-350 • Important toxicologic data.
8. Vertes V, Haynie R. Comparative pharmacokinetics of captopril, enalapril and quinapril. Am J Cardiol 1992;69(10):8C-16C
9. Plosker GL, Sorkin EM. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders. Drugs 1994;48(2):227-52 • A review including comparisons with other ACE-inhibitors.
10. Wadworth AN, Brogden RN. Quinapril. A review of its pharmacological properties, and therapeutic efficacy in cardiovascular disorders. Drugs 1991;41(3):378-399
11. Ferry JJ, Horvath AM, Sedman AJ, et al. Influence of food on the pharmacokinetics of quinapril and its active diacid metabolite , CI-928. J Clin Pharmacol 1987;27(5):397-399
12. Accupril U.S. physician prescribing information, Pfizer, 2006. Available from: http://media.pfizer.com/files/products/uspi-accupril.pdf [Last accessed 9 June 2009]
13. Blumer JL, Daniels SR, Dreyer WJ, et al. Pharmacokinetics of quinapril in children: assessment during substitution for chronic angiotensin-converting enzyme inhibitor treatment. J Clin Pharmacol 2003;43(2):128-132
14. Horvath A, Olson S, Ferry J, et al. Pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients with hepatic impairment. J Clin Pharmacol 1988;28:917
15. Squire IB, Macfayden RJ, Lees KR, et al. Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure. Br J Clin Pharmacol 1994;38(2):117-123 (Pubitemid 24247752)
16. Begg EJ, Robson RA, Ikram H, et al. The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure. Br J Clin Pharmacol 1994;37(3):302-304 (Pubitemid 24212193)
17. Wolter K, Fritschka E. Pharmacokinetics and pharmacodynamics of quinaprilat after low dose quinapril in patients with terminal renal failure. Eur J Clin Pharmacol 1993;44(Suppl 1):S53-6 (Pubitemid 23098482)
18. Yamada S, Muraoka I, Kato K, et al. Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. Biol Pharm Bull 2003;26(6):872-875 (Pubitemid 39655312)
19. Begg EJ, Robson RA, Gardiner SJ, et al. Quinapril and its metabolite quinaprilat in human milk. Br J Clin Pharmacol 2001;51(5):478-481
20. Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001;88(Suppl):1-20 (Pubitemid 33022712)
21. Sedman AJ, Posvar E. Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure. Angiology 1989;40:360-369 (Pubitemid 19108870)
22. Materson BJ. Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril. Am J Cardiol 1992;69(10):46C-53C
23. Johnston CI, Fabris B, Yamada H, et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens Suppl 1989;7(5):S11-6 (Pubitemid 19269331)
24. Kinoshita A, Urata H, Bumpus M, et al. Measurement of angiotensin I converting enzyme inhibition in the heart. Circ Res 1993;73:51-60 (Pubitemid 23173055)
25. Oosterga M, Voors AA, Buikema H, et al. Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. QUO VADIS investigators. Cardiovasc Drugs Ther 2000;14(1):55-60 • Proof of vascular ACE inhibition in humans. (Pubitemid 30139222)
26. Givertz MM. Manipulation of the renin-angiotensin system. Circulation 2001;104(5):14-18
27. Benetos A, Levy BI, Lacolley P, et al. Role of angiotensin II and bradykinin on aortic collagen following converting enzyme inhibition in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997;17(11):3196-3201 (Pubitemid 28016077)
28. Kaplan HR, Taylor DG, Olson SC. Quinapril: overview of preclinical data. Clin Cardiol 1990;13(6 Suppl 7):VII6-12
29. Houben AJHM, Kroon AA, deHaan CHA, et al. Quinaprilat-induced vasodilatation in forearm vasculature of patients with essential hypertension: comparison with enalaprilat. Cardiovasc Drugs Ther 2000;14:657-663
30. Kobayashi N, Honda T, Yoshida K, et al. Critical role of bradykinin-eNOS and oxidative stress-LOX-1 pathway in cardiovascular remodeling under chronic angiotensin-converting enzyme inhibition. Atherosclerosis 2006;187(1):92-100 (Pubitemid 43817007)
31. Frank GJ, Knapp LE, Olson SC, et al. Overview of quinapril, a new ACE- inhibitor. J Cardiovasc Pharmacol 1990;15(Suppl 2):S14-23
32. Neub M, Legler U. Pharmacokinetics of intravenous quinaprilat following rising single and multiple doses [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1991;343(Suppl):R128
33. Culy CR, Jarvis B. Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs 2002;62(2):339-385 •• Detailed review with focus on clinical application of quinapril. (Pubitemid 34169440)
34. Holtz J, Allgeier J, Goetz R, et al. Bradykinin contributes to the cardiac reparation by quinapril in rats with hypertensive left ventricular hypertrophy. Eur Heart J 1992;13(Suppl 2):252
35. De Castro S, Pellicia F, Cartoni D, et al. Effects of angiotensin-converting enzyme inhibition on left ventricular geometric patterns in patients with essential hypertension. J Clin Pharmacol 1996;36(12):1141-1148 (Pubitemid 27056942)
36. Franz I-W, Tönnesmann U, Müller JFM. Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibition. Am J Hypertens 1998;11:631-639 (Pubitemid 28318627)
37. Drescher T. Einfluß des ACE-Hemmers quinaprilat auf die perfusion und kontraktion des in situ schlagenden rattenherzens nach repetitiver ischämie und reperfusion. Available from: http://www.ub.uni-heidelberg.de/ archiv/81 [Last accessed 9 June 2009]
38. Kieback AG, Grohmann A, Baumann G, et al. Haemodynamic effects of intravenous quinaprilat in comparison to sodium nitroprusside in patients with chronic heart failure. Int J Cardiol 2007;121:102-104 (Pubitemid 47299259)
39. Mitrovic V, Mudra H, Bonzel T, et al. Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure. Clin Pharmacol Ther 1996;59(6):686-698 (Pubitemid 26233425)
40. Krum H, Karrasch J, Hamer A, et al. Effect of angiotensin-converting enzyme inhibitor dosing interval on functional parameters in patients with chronic heart failure. Am Heart J 1998;135:237-241 (Pubitemid 28139162)
41. Zi M, Carmichael N, Lye M. The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther 2003;17(2):133-139 (Pubitemid 37174687)
42. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE inhibitor trials. JAMA 1995;273(18):1450-1456
43. Pilote L, Abrahamowicz M, Eisenberg M, etal. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ 2008;178(10):1303-1311
44. van Beusekom HMM, Ferrero V, Ribichini F, etal. Quinaprilat-eluting stents do not attenuate intimal thickening following stenting in porcine coronary arteries. Atherosclerosis 2009, doi:10.1016/j.atherosclerosis.2008.11. 029 • Important information on coronary restenosis in porcine arteries.
45. Pitt B, O'Neill B, Feldman R, et al. The quinapril ischemic event trial (QUIET): evaluation of chronic ace inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87(9):1058-1063 • Clinical data in patients with ischemic heart disease. (Pubitemid 32710319)
46. Pepine CJ, Rouleau JL, Annis K, et al. Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol 2003;42(12):2049-2059 (Pubitemid 37549883)
47. Otsuka M, Yamamoto H, Okimoto T, et al. Long-term effects of quinapril with high affinity for tissue angiotensin-converting enzyme after coronary intervention in Japanese. Am Heart J 2004;147(4):662-668 (Pubitemid 38900452)
48. Okimoto T, Imazu M, Hayashi Y, et al. Quinapril with high affinity to tissue angiotensin-converting enzyme inhibitor reduces restenosis after percutaneous transcatheter coronary intervention. Cardiovasc Drugs Ther 2001;15(4):323-329 (Pubitemid 33121986)
49. Kondo J, Sone T, Tsuboi H, etal. Effect of quinapril on intimal hyperplasia after coronary stenting as assessed by intravascular ultrasound. Am J Cardiol 2001;87(4):443-456 (Pubitemid 32150004)
50. Meurice T, Bauters C, Hermant X, et al. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. Lancet 2001;357:1321-1324 (Pubitemid 32441530)
51. Ujiie Y, Hirosaka A, Mitsugi M, et al. Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis. Int Heart J 2006;47(2):173-184
52. Yamazaki T, Taniguchi I, Kurusu T, et al. Effect of amlodipine on vascular responses after coronary stenting compared with an angiotensin- converting enzyme inhibitor. Circ J 2004;68(4):328-333 (Pubitemid 38470706)
53. Kossmehl P, Kurth E, Faramarzi S, et al. Mechanisms of apoptosis after ischemia and reperfusion: role of the renin-angiotensin system. Apoptosis 2006;11(3):347-358
54. Hoshida S, Yamashita N, Kawahara K, et al. Amelioration by quinapril of myocardial infarction induced by coronary occlusion/reperfusion in a rabbit model of atherosclerosis: possible mechanisms. Circulation 1999;99(3):434-440 (Pubitemid 29051271)
55. Hu K, Gaudron P, Anders H-J, et al. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin. Cardiovasc Res 1998;39(2):401-412 (Pubitemid 28346536)
56. Ciulla MM, Montelatici E, Ferrero S, et al. Potential advantages of cell administration on the inflammatory response compared to standard ACE inhibitor treatment in experimental myocardial infarction. J Transl Med 2008;6:30 (Pubitemid 351917275)
57. Gaudron P, Kugler I, Hu K, etal. Effect of quinapril initiated during progressive remodeling in asymptomatic patients with healed myocardial infarction. Am J Cardiol 2000;86:139-144 (Pubitemid 30410720)
58. Oosterga M, Voors AA, Pinto YM, et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). Quinapril on vascular ace and determinants of ischemia. Am J Cardiol 2001;87(5):542-546 • Valuable clinical data in patients after coronary artery bypass surgery.
59. Kwapisz MM, Müller M, Schindler E, et al. The effect of intravenous quinaprilat on plasma cytokines and hemodynamic variables during cardiac surgery. J Cardiothorac Vasc Anesth 2004;18(1):53-58 (Pubitemid 38240761)
60. Rouleau JL, Warnica WJ, Baillot R, et al. Effects of angiotensin- converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation 2008;117(1):24-31 •• Important trial on the effects of quinapril in low-risk patients after coronary artery bypass surgery. (Pubitemid 350291178)
61. Ren J, Li H, Prior BM, etal. Angiotensin converting enzyme inhibition enhances collateral artery remodeling in rats with femoral artery occlusion. Am J Med Sci 2008;335(3):177-187
62. Schindler C, Mueller A, Bramlage P, et al. Comparison of selective AT1-receptor blockade versus ACE inhibition for restenosis prophylaxis in patients with peripheral occlusive arterial disease after stent angioplasty: a randomized, controlled, proof-of-concept study. Angiology 2007;58(6):710-716
63. Sen S, Kanter M, Ustundag S, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy. Ren Fail 2008;30(10):1023-1033
64. Lim SC, Koh AF, Goh SK, et al. Angiotensin receptor antagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type2 diabetes and albuminuria-a randomized crossover study. Diabetes Obes Metab 2007;9(4):477-482
65. Guiducci S, Cerinic MM. Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis. Nat Clin Pract Rheumatol 2008;4(6):288-289 (Pubitemid 351791435)
66. Gliddon AE, Doré CJ, Black CM, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 2007;56(11):3837-3846
67. Gryglewski RJ, Uracz W, Swies J, et al. Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins. Ann NY Acad Sci 2001;947:229-245 (Pubitemid 34059918)
68. Delli Gatti C, Osto E, Kouroedov A, et al. Pulsatile stretch induces release of angiotensin II and oxidative stress in human endothelial cells: effects of ACE inhibition and AT1 receptor antagonism. Clin Exp Hypertens 2008;30(7):616-627
69. Ceconi C, Francolini G, Bastianon D, et al. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: invitro and invivo studies. Cardiovasc Drugs Ther 2007;21(6):423-429 (Pubitemid 50003315)
70. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vacular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;95(5):1115-1118 (Pubitemid 27097818)
71. Haefeli WE, Linder L, Lüscher TF. Quinaprilat induces arterial vasodilation mediated by nitric oxide in humans. Hypertension 1997;30(4):912-917 (Pubitemid 27441121)
72. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94(3):258-265
73. Kovacs I, Toth J, Tarjan J, Koller A. Correlation of flow mediated dilation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE. Eur J Heart Fail 2006;8(5):451-459 (Pubitemid 44236167)
74. Hornig B, Arakawa N, Haussmann D, et al. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998;98:2842-8 • Important study on endothelial dysfunction, questioning the ACE-inhibitor 'class effect'.
75. Farkas K, Fàbiàn E, Nagy L. Quinapril improves endothelial function in postmenopausal hypertensive patients. Kidney Blood Press Res 2008;31(4):226-233
76. Korkmaz H, Karaca I, Koç M, etal. Early effects of treatment with nebivolol and quinapril on endothelial function in patients with hypertension. Endothelium 2008;15(3):149-155
77. Steinhauff S, Pehlivanli S, Bakovic-Alt R, et al. Beneficial effects of quinaprilat on coronary vasomotor function, endothelial oxidative stress, and endothelin activation after human heart transplantation. Transplantation 2004;77(12):1859-1865 (Pubitemid 38822209)
78. Koskinen P, Manninen V, Eisalo A. Quinapril and blood lipids. Br J Clin Pharmacol 1988;26:478-480
79. Fogari R, Lusardi P, Megellini A, et al. Effect of antihypertensive therapy with quinapril on blood lipids. Adv Ther 1994;11(3):144-153 (Pubitemid 24211011)
80. Undas A, Brummel-Ziedins KE, Potaczek DP, et al. Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28days of therapy. J Thromb Haemost 2006;4(11):2397-2404 (Pubitemid 44575435)
81. Kontopoulos AG, Athyros VG, Papageorgiou AA, etal. Effect of quinapril or metoprolol on heart rate variability in post-myocardial infarction patients. Am J Cardiol 1996;77(4):242-246
82. Andrews LK, Anderson JA, Kim SN, et al. Chronic toxicity evaluation of the nonsulfhydryl angiotensin converting enzyme inhibitor quinapril [abstract 729]. Toxicologist 1986;6:181
83. Anderson JA, Fitzgerald JE, Jayasekaka U, et al. Preclinicla toxicological evaluation of an angiotensin II converting enzyme inhibitor of the tetrahydroquinoline series [abstract 2623]. Fed Proc 1984;43:733
84. Yuan H, Feng B, Yu Y, etal. Renal organic anion transporter mediated drug-drug interaction between gemcabene and quinapril. J Pharmacol Exp Ther 2009. [Epub ahead of print]
85. Dasandi B, Shah S, Shivprakash. Determination of quinapril and quinaprilat in human plasma by ultraperformance liquid chromatography- electrospray ionization mass spectometry. Biomed Chromatogr 2009;23(5):492-498
86. Canter D, Frank G. ACE inhibitors in the treatment of hypertension in the older patient. Eur Heart J 1990;11(Suppl D):33-43 (Pubitemid 20161996)